Sort   by:  
 Page size 
Acute myeloid leukemia (AML) cells rely on phospho-signaling pathways to gain unlimited proliferation potential. Here, we used domain-focused CRISPR screening to identify the nuclear phosphatase SCP4 as a dependency in AML, yet this enzyme is dispensable in normal hematopoietic progenitor cells. Usi...
2025-05-29 | MTBLS3707 | MetaboLights
Acute myeloid leukemia (AML) is a hematologic malignancy with a poor prognosis. We discovered that BMAL1 is a ferroptosis suppressor. Furthermore, it was also found to be overexpressed in AML patients, affecting the cell cycle and promoting tumor cell growth and progression. In this study, we furthe...
2025-01-24 | MTBLS11557 | MetaboLights

Acute myeloid leukemia (AML) is an aggressive disease with a high relapse rate. In this study, we map the metabolic profile of CD34+(CD38low/-) AML cells and the extracellular vesicle signatures in circulation from AML patients at diagnosis. CD34+ AML cells display high antioxidant glutathione le...

2024-12-04 | MTBLS11523 | MetaboLights

Acute Myeloid Leukemia (AML) commonly relapses after initial chemotherapy response. We assessed metabolic adaptations in chemoresistant cells in vivo before overt relapse, identifying altered branched-chain amino acid (BCAA) levels in patient-derived xenografts (PDX) and immunophenotypically iden...

2025-07-19 | MTBLS10255 | MetaboLights

Acute myeloid leukemia (AML) is an aggressive disease with a high relapse rate. In this study, we map the metabolic profile of CD34+(CD38low/-) AML cells and the extracellular vesicle signatures in circulation from AML patients at diagnosis. CD34+ AML cells display high antioxidant glutathione le...

2024-12-04 | MTBLS11746 | MetaboLights
Label-free quantitation dataset from 44 representative Acute Myeloid Leukemia (AML) patients from the LAML TCGA dataset, and 6 healthy bone marrow derived controls including 3 lineage-depleted and 3 CD34+ selected bone marrows.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2022-03-09 | MSV000089029 | MassIVE
A deep-scale proteome and phosphoproteome database from 44 representative Acute Myeloid Leukemia (AML) patients from the LAML TCGA dataset, and 6 healthy bone marrow derived controls including 3 lineage-depleted and 3 CD34+ selected bone marrows.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2022-03-07 | MSV000089012 | MassIVE
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) show heterogeneous treatment outcomes. We used gene expression profiling to develop a gene signature that predicts overall survival (OS) in CN-AML. Based on data from 163 patients treated in the German AMLCG 1999 trial and analyzed...
ORGANISM(S): Homo sapiens 
Acute myeloid leukemia (AML) is a heterogeneous disease in respect of molecular aberrations and prognosis. We used gene expression profiling of 562 patients treated in the German AMLCG 1999 trial to develop a gene signature that predicts survival in AML. Analysis of 562 samples (140 HGU-133plus2; 42...
ORGANISM(S): Homo sapiens 
Myeloproliferative neoplasm (MPN) or post-MPN acute myeloid leukemia patient bone marrow aspirates were sorted for CD34+ hematopoietic stem and progenitor cells (HSPCs), followed by 10x 3' single cell RNA sequencing and long read sequencing to study the consequences of mutation combination on HSPCs.
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size